FDA
Baxfendy wins first-in-class FDA approval for uncontrolled hypertension
Photo credit: Astraeneca
Clinical takeaway: Consider baxdrostat as an add-on option in adults with uncontrolled or resistant hypertension on multiple agents, particularly when aldosterone-driven disease is suspected.
Despite widespread use of combination therapy, up to half of patients with hypertension remain uncontrolled, leaving a major gap in cardiovascular risk reduction that new mechanistic approaches may help address.
On May 14, 2026, FDA approved Baxfendy (baxtrostat), the first aldosterone synthase inhibitor (ASI) for adults with hypertension inadequately controlled on existing therapies, introducing a new mechanism targeting aldosterone production. The once-daily oral agent is intended for use in combination with standard antihypertensive medications and addresses a key hormonal driver of persistent blood pressure elevation.
Approval was based on results from the phase 3 BaxHTN trial, which enrolled 796 patients with uncontrolled or resistant hypertension already receiving at least two medications, including a diuretic. At 12 weeks, baxdrostat 2 mg reduced mean seated systolic blood pressure by 15.7 mmHg from baseline, with a placebo-adjusted reduction of 9.8 mmHg (p<0.001). The 1 mg dose achieved a 14.5 mmHg reduction, with an 8.7 mmHg placebo-adjusted difference (p<0.001). Blood pressure reductions were consistent across uncontrolled and resistant subgroups.
The drug was generally well tolerated, with no unexpected safety signals observed across the trial and longer-term follow-up. Investigators also reported preserved cortisol levels despite suppression of aldosterone, supporting the drug’s selectivity for CYP11B2.
“We have been waiting for an innovative medication like Baxfendy for hypertension for many years,” said primary investigator Dr. Bryan Williams. “Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension… the nearly double-digit placebo-adjusted systolic blood pressure reduction… is exciting and clinically meaningful.”
Aldosterone excess contributes to sodium retention, vascular dysfunction, and cardiorenal risk, making it a compelling therapeutic target, especially in resistant hypertension. Epidemiologic data suggest that a 10 mmHg reduction in systolic blood pressure may lower the risk of major cardiovascular events by about 20%, underscoring the clinical relevance of the observed reductions.
With millions of patients remaining uncontrolled despite multidrug regimens, baxdrostat represents the first major pharmacologic advance in hypertension in decades and may expand options for patients at highest cardiovascular risk.
Source: Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension. AstraZeneca. May 2026.